Meda: The Ashtavarga Solomon's Seal, Evidence & Safety

TL;DR

Meda is one of the eight Ashtavarga herbs: the rhizome of Polygonatum verticillatum, a traditional rejuvenative (rasayana) ingredient of Chyawanprash. No human trials were identified. One animal study in rats found injected rhizome extract at 50–200 mg/kg reduced fever comparably to aspirin, with no demonstrated anti-seizure effect. Human efficacy and safety remain unstudied, and this article gives no dosage.

What it is

Meda is the rhizome (underground stem) of Polygonatum verticillatum (Linn.) Allioni, a herb of the lily family (Liliaceae) (Balkrishna et al., J Nat Ayurvedic Med 2018). It is one of the Ashtavarga, the classical group of eight herbs prized as rasayana (rejuvenatives), and its rhizome is used in Chyawanprash and related Ayurvedic formulations (Balkrishna et al. 2018). It should not be confused with Mahameda (Polygonatum cirrhifolium), its Ashtavarga partner (Balkrishna et al. 2018). The identity of Ashtavarga herbs has been historically debated, and the 2018 review notes ambiguity in the literature; this article follows its association of Meda with P. verticillatum.

Traditional use

Within Ayurveda, the Ashtavarga group, Meda included, is classified as rasayana and described as jivaniya (vitality-promoting) and vayasthapana (age-sustaining), the rejuvenative qualities behind its inclusion in Chyawanprash and related formulations (Balkrishna et al. 2018). The 2018 review notes that biochemical, phytochemical, and biological investigation of the Ashtavarga plants is limited and that scientific validation is still needed (Balkrishna et al. 2018). Specific classical indications for Meda alone are thinly documented in the sources opened for this article; these are traditional attributions, not clinical proof.

What modern research says

Fever reduction (animal study)

The single most substantive study of Meda tested crude methanol extracts of its rhizomes and aerial parts in rats with Brewer's-yeast-induced fever, at intraperitoneal doses of 50, 100, and 200 mg/kg (Khan et al., Phytother Res 2013). Both extracts produced dose-dependent fever reduction; the rhizome extract at 200 mg/kg gave 82.2% protection, comparable to aspirin's 88.5% at 100 mg/kg. The same study found no anti-seizure activity in the pentylenetetrazole convulsion model. Animal study with injected extracts: consistent with traditional interest in fever, but not evidence that oral Meda reduces fever in humans.

What is missing

No human trial of Meda was found: no efficacy, no safety, no dose-finding study in people. The evidence base is one animal pharmacology study. Note also that the study used injected crude extracts, not a traditional oral preparation, which further limits what can be inferred.

Safety & contraindications

There are no human safety data for Meda: no established dose, no interaction data, no pregnancy or breastfeeding information. Do not extrapolate from the animal study, which used injected crude extracts rather than traditional oral preparations (Khan et al. 2013). As with the other Ashtavarga herbs, identity confusion, rarity, and commercial substitution are documented concerns for the group (Balkrishna et al. 2018). Consult a qualified clinician.

FAQs

What is Meda?

Meda is the rhizome of Polygonatum verticillatum (Linn.) Allioni, a herb of the lily family (Liliaceae) and one of the eight Ashtavarga herbs prized as rasayana (rejuvenatives), with its rhizome used in Chyawanprash and related Ayurvedic formulations (Balkrishna et al., J Nat Ayurvedic Med 2018). It should not be confused with Mahameda (Polygonatum cirrhifolium), its Ashtavarga partner.

Does Meda reduce fever?

In one animal study, crude methanol extracts of the rhizome and aerial parts reduced Brewer's-yeast-induced fever in a dose-dependent manner at injected doses of 50, 100, and 200 mg/kg. The rhizome extract at 200 mg/kg gave 82.2% protection, close to aspirin's 88.5% at 100 mg/kg (Khan et al., Phytother Res 2013). The same study found no anti-seizure effect. Animal data with injected extracts: not evidence that oral Meda reduces fever in humans.

Are there any human trials?

No. The research record for Meda is a single animal pharmacology study on fever and seizures, plus group-level reviews of the Ashtavarga plants noting that biochemical and biological investigation of these plants remains limited (Khan et al., Phytother Res 2013; Balkrishna et al., J Nat Ayurvedic Med 2018). No human efficacy, safety, or dose-finding study was identified.

What is Meda traditionally used for?

Within Ayurveda, the Ashtavarga group, Meda included, is classified as rasayana and described as jivaniya (vitality-promoting) and vayasthapana (age-sustaining), the rejuvenative qualities behind its inclusion in Chyawanprash and related formulations (Balkrishna et al., J Nat Ayurvedic Med 2018). Specific classical indications for Meda alone are thinly documented in the sources reviewed; these are traditional attributions, not clinical proof.

Is Meda safe?

Unknown in humans: no safety data, no established dose, and no interaction, pregnancy, or breastfeeding information were identified. Do not extrapolate from the animal study, which used injected crude extracts rather than traditional oral preparations (Khan et al., Phytother Res 2013). As with the other Ashtavarga herbs, commercial material may be substituted or adulterated. Consult a qualified clinician rather than relying on traditional reputation.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.